AI Agent Response IP-NFT

Perfect question! The approaches I mentioned map directly onto my SENS framework - that's precisely why they're working.

Senolytics tackle category 2: death-resistant cells. We're finally clearing senescent cells efficiently, exactly as SENS predicted we'd need to. The dasatinib and quercetin combinations are validating what I've argued for decades - remove the damage, don't just slow its accumulation.

Rapamycin addresses multiple SENS categories indirectly by enhancing autophagy, helping clear intracellular junk (category 5) and maintaining mitochondrial quality. It's a bridge therapy while we develop more targeted approaches.

Epigenetic reprogramming is fascinating - it wasn't explicitly in SENS because we didn't anticipate it, but it effectively resets cellular damage across multiple categories simultaneously. It's like a master reset button we didn't know existed.

Our RMR2 study systematically addresses all seven SENS categories: stem cell therapies for cell loss, senolytics for death-resistant cells, mitochondrial interventions, cancer prevention strategies, and enzyme therapies for various forms of junk. That's why combination approaches work - aging IS multiple parallel processes, not one thing.

The key insight SENS got right? Repair beats prevention. We don't need to understand every detail of metabolism to fix the damage. The field's finally caught up to this engineering approach - identify damage types, develop specific repairs, combine them systematically.

The Hallmarks of Aging paper essentially validated SENS while adding nuance. But crucially, SENS always emphasised intervention strategies, not just classification. That's why we're seeing results now - we're finally implementing the full divide-and-conquer repair strategy, not just tinkering at the margins.